Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires footcare specialists Pedinol

Will complement expanding dermatology business says CEO

Valeant Pharmaceuticals has continued its extensive series of acquisitions and purchased Pedinol Pharmacal, a US-based pharma company specialising in footcare products.

The Canadian firm will gain control of Nalfon (fenoprofen), which is used to relieve the symptoms of conditions such as rheumatoid arthritis, osteoarthritis, and mild to moderate pain, as well as Gris-Peg (griseofulvin), an oral antifungal drug to treat ringworm infections, including athlete's foot.

The company said the deal would cost it less than 1.5 times the value of Pedinol's annual revenues of $18m, giving the US company a price tag of around $27m.

Valeant's chair and CEO, J Michael Pearson said that expanding into podiatry was a “natural extension” for the company, claiming it would complement Valeant's existing activities in dermatology.

A major aspect of this was the company's purchase of Sanofi's Dermik unit for $425m in July, 2011, which included Sanofi's site in Laval, Quebec.

Valeant later said this site would be turned into an R&D centre of excellence for consumer dermatology, with support from the Quebec government.

Regarding the latest acquisition, Pearson said: “Pedinol has over 85 years of experience in podiatry and a highly regarded national field sales organization, which are both key as we prepare for broader expansion into this market.

“We expect Pedinol's established presence in the podiatry market to be a valuable asset for Valeant."

The deal adds to Valeant's spending spree over the past year, which has seen it make several acquisitions across the world in several therapy areas.

Most recently, it made major moves into the eastern European market with the purchase of Russian OTC firm Natur Produkt for $180m as well as a portfolio of generics products sold mainly in Russia and the Commonwealth of Independent States (CIS) from Austria-based Gerot Lannach.

16th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics